American pharmaceutical company Pfizer, which invented drugs like Viagra, has claimed that by the end of October this year, their vaccine will be ready, Pfizer CEO Albert Burla quoted "The Times of Israel" if all goes well And if we get lucky, there will be a vaccine by the end of October.
Britain's GlaxoSmithKline laid out plans today to produce 1 billion doses of vaccine efficacy boosters, or adjuvants, next year as the race to develop and produce a successful solution to the coronavirus crisis heats up.
Each of these companies is working with their partners to develop a vaccine to prevent the disease.
According to the World Health Organization, it is important to evaluate as many vaccines as possible, and we can not predict how many will be effective.More news: Sony Schedules PS5 Event for June 4
The report also highlighted the warnings from experts saying the challenges could be "daunting" as the estimates show that about 15 million doses would be required to stop the pandemic. The ongoing trial allows for the evaluation of the various mRNA candidates simultaneously in order to identify the safest and potentially most efficacious candidate in a greater number of volunteers. He, however, said "we are running against time".
Among those, one of the furtherest ahead in development is an adenovirus-based vaccine being developed by the University of Oxford and AZ, which according to the drugmaker's CEO Pascal Soriot completed phase 1/2 trials last week, with data expected imminently.
More than 120 vaccines are now being developed worldwide.
Soriot discussed the challenge posed by declining infection rates in Europe as well as the United States, which could make it hard to show that the vaccines work using healthy volunteer studies.More news: India to ease lockdown despite new daily infections record
Once a working vaccine is developed, one of the biggest obstacles to putting out the amount needed could surprisingly be that there are not enough glass vials to store the doses in.
Speaking on behalf of J&J, chief scientific officer Paul Stoffels said its adenovirus-based vaccine is based on a technology that has already been used to generate immunisations for Ebola, RSV, HIV and Zika, allowing the SARS-CoV-2 project to get underway rapidly.
Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) said it was widely accepted that once a successful Covid-19 vaccine is created it will not be available in sufficient quantities from the beginning.
One challenge could be that some of the vaccines being worked on require storage at very low temperatures, which could be hard in places lacking the proper infrastructure.More news: Billie Eilish Slams ''All Lives Matter'' Movement and Addresses ''White Privilege''
"IP is absolutely fundamental to our industry", GSK chief Emma Walmsley said.